NAS:INCY (USA) Also trade in: Austria Germany UK

Incyte Corp

$ 86.92 -1.78 (-2.01%)
Volume: 1,229,499 Avg Vol (1m): 1,365,335
Market Cap $: 18.64 Bil Enterprise Value $: 17.08 Bil
P/E (TTM): 74.28 P/B: 9.05
Earnings Power Value 9.64
Net Current Asset Value 5.69
Tangible Book 7.92
Projected FCF 12.52
Median P/S Value 175.54
Graham Number 14.44
Peter Lynch Value 0
DCF (FCF Based) 0
DCF (Earnings Based) 0
1Y (-%)

Financial Strength : 9/10

GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
Current vs industry vs history
Cash-to-Debt 89.59
Cash-To-Debt ranked lower than
50.65% of 1078 companies
in the Biotechnology industry.
Industry Max: 20856.43, Med: 64.02, Min: 0.01
INCY: 89.59
Ranked among companies with meaningful Cash-To-Debt only.
Cash-To-Debt range over the past 10 years
Min: 0.35, Med: 1.56, Max: 10000
Current: 89.59
0.35
10000
Equity-to-Asset 0.76
Equity-to-Asset ranked higher than
55.18% of 763 companies
in the Biotechnology industry.
Industry Max: 3.47, Med: 0.69, Min: -9.46
INCY: 0.76
Ranked among companies with meaningful Equity-to-Asset only.
Equity-to-Asset range over the past 10 years
Min: -1.83, Med: 0.25, Max: 0.92
Current: 0.76
-1.83
0.92
Debt-to-Equity 0.01
Debt-to-Equity ranked higher than
99.40% of 500 companies
in the Biotechnology industry.
Industry Max: 35.66, Med: 0.28, Min: 0.01
INCY: 0.01
Ranked among companies with meaningful Debt-to-Equity only.
Debt-to-Equity range over the past 10 years
Min: -17.62, Med: 0.01, Max: 97.27
Current: 0.01
-17.62
97.27
Debt-to-EBITDA 0.06
Debt-to-EBITDA ranked lower than
100.00% of 196 companies
in the Biotechnology industry.
Industry Max: 1208.58, Med: 2.04, Min: 0.01
INCY: 0.06
Ranked among companies with meaningful Debt-to-EBITDA only.
Debt-to-EBITDA range over the past 10 years
Min: -14.97, Med: 1.7, Max: 173.16
Current: 0.06
-14.97
173.16
Interest Coverage 198.65
Interest Coverage ranked lower than
100.00% of 500 companies
in the Biotechnology industry.
Industry Max: 22756408, Med: 10000, Min: 0.12
INCY: 198.65
Ranked among companies with meaningful Interest Coverage only.
Interest Coverage range over the past 10 years
Min: 0.02, Med: 1.11, Max: 198.65
Current: 198.65
0.02
198.65
Piotroski F-Score 7
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 17.88
DISTRESS
GREY
SAFE
Beneish M-Score -2.65
Not Manipulator
Manipulator
WACC vs ROIC %
ROIC 56.87%
WACC 8.07%

Profitability & Growth : 7/10

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
Current vs industry vs history
Operating Margin % 14.85
Operating Margin ranked higher than
67.80% of 792 companies
in the Biotechnology industry.
Industry Max: 46829238.82, Med: -113.97, Min: -1969600
INCY: 14.85
Ranked among companies with meaningful Operating Margin only.
Operating Margin range over the past 10 years
Min: -1508.56, Med: -0.28, Max: 14.85
Current: 14.85
-1508.56
14.85
Net Margin % 12.66
Net Margin ranked higher than
69.32% of 792 companies
in the Biotechnology industry.
Industry Max: 49899604.52, Med: -111.91, Min: -2150400
INCY: 12.66
Ranked among companies with meaningful Net Margin only.
Net Margin range over the past 10 years
Min: -2286.78, Med: -16.84, Max: 12.66
Current: 12.66
-2286.78
12.66
ROE % 13.78
ROE ranked higher than
73.21% of 989 companies
in the Biotechnology industry.
Industry Max: 326.78, Med: -42.82, Min: -100794.12
INCY: 13.78
Ranked among companies with meaningful ROE only.
ROE range over the past 10 years
Min: -30.55, Med: 10.38, Max: 35.29
Current: 13.78
-30.55
35.29
ROA % 10.02
ROA ranked higher than
74.82% of 1084 companies
in the Biotechnology industry.
Industry Max: 224.74, Med: -34.77, Min: -3751.92
INCY: 10.02
Ranked among companies with meaningful ROA only.
ROA range over the past 10 years
Min: -45.58, Med: -10.12, Max: 10.02
Current: 10.02
-45.58
10.02
ROC (Joel Greenblatt) % 85.39
ROC (Joel Greenblatt) ranked higher than
71.72% of 1036 companies
in the Biotechnology industry.
Industry Max: 641137.84, Med: -521.46, Min: -3427023.81
INCY: 85.39
Ranked among companies with meaningful ROC (Joel Greenblatt) only.
ROC (Joel Greenblatt) range over the past 10 years
Min: -2540.65, Med: 13.38, Max: 115.22
Current: 85.39
-2540.65
115.22
3-Year Total Revenue Growth Rate 35.70
3-Year Revenue Growth Rate ranked higher than
83.72% of 651 companies
in the Biotechnology industry.
Industry Max: 906.3, Med: 1.1, Min: -100
INCY: 29.4
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
3-Year Revenue Growth Rate range over the past 10 years
Min: -61.4, Med: 29.1, Max: 523.4
Current: 29.4
-61.4
523.4
3-Year Total EBITDA Growth Rate 20.60
3-Year EBITDA Growth Rate ranked lower than
100.00% of 802 companies
in the Biotechnology industry.
Industry Max: 1406.7, Med: 4.6, Min: -2038.5
INCY: 15.1
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
3-Year EBITDA Growth Rate range over the past 10 years
Min: 0, Med: -91.7, Max: 226.7
Current: 15.1
0
226.7
3-Year EPS w/o NRI Growth Rate 157.10
3-Year EPS w/o NRI Growth Rate ranked lower than
93.97% of 763 companies
in the Biotechnology industry.
Industry Max: 1406.7, Med: 5.7, Min: -2103.4
INCY: 157.1
Ranked among companies with meaningful 3-Year EPS w/o NRI Growth Rate only.
3-Year EPS w/o NRI Growth Rate range over the past 10 years
Min: 0, Med: -29.1, Max: 157.1
Current: 157.1
0
157.1

» INCY's 30-Y Financials

Financials (Next Earnings Date: 2019-07-31)

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NAS:INCY

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Biotechnology » Biotechnology    NAICS : 541714    SIC : 8731
Compare XKRX:207940 XKRX:068270 NAS:BMRN XBRU:UCB OCSE:NZYM B HKSE:01177 HKSE:02269 OCSE:GEN NAS:SGEN NAS:IONS NAS:SAGE NAS:SRPT NAS:JAZZ HKSE:06160 NAS:TECH NAS:ALNY SZSE:000661 NAS:NBIX NAS:MRNA NAS:BLUE
Traded in other countries ICY.Germany 0J9P.UK
Address 1801 Augustine Cut-Off, Wilmington, DE, USA, 19803
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant, which is licensed by Eli Lilly, and oncology drug Iclusig for chronic myeloid leukemia. Incyte's pipeline includes a broad array of oncology and autoimmune programs, including IDO inhibitor epacadostat and next-generation JAK inhibitor itacitinib.

Ratios

Current vs industry vs history
PE Ratio (TTM) 74.28
PE Ratio ranked lower than
100.00% of 248 companies
in the Biotechnology industry.
Industry Max: 5600, Med: 28.79, Min: 0.01
INCY: 74.28
Ranked among companies with meaningful PE Ratio only.
PE Ratio range over the past 10 years
Min: 63.21, Med: 218.06, Max: 11323
Current: 74.28
63.21
11323
Forward PE Ratio 41.84
Forward P/E ranked lower than
76.62% of 77 companies
in the Biotechnology industry.
Industry Max: 769.23, Med: 28.41, Min: 3.89
INCY: 41.84
Ranked among companies with meaningful Forward P/E only.
N/A
PE Ratio without NRI 74.28
PE without NRI ranked lower than
100.00% of 243 companies
in the Biotechnology industry.
Industry Max: 5600, Med: 28.64, Min: 0.01
INCY: 74.28
Ranked among companies with meaningful PE without NRI only.
PE without NRI range over the past 10 years
Min: 63.21, Med: 218.06, Max: 11323
Current: 74.28
63.21
11323
Price-to-Owner-Earnings 101.66
Price-to-Owner-Earnings ranked lower than
100.00% of 145 companies
in the Biotechnology industry.
Industry Max: 305714.29, Med: 34.35, Min: 0.21
INCY: 101.66
Ranked among companies with meaningful Price-to-Owner-Earnings only.
Price-to-Owner-Earnings range over the past 10 years
Min: 10.73, Med: 99.13, Max: 553.9
Current: 101.66
10.73
553.9
PB Ratio 9.05
PB Ratio ranked lower than
73.49% of 962 companies
in the Biotechnology industry.
Industry Max: 2236, Med: 4.1, Min: 0.05
INCY: 9.05
Ranked among companies with meaningful PB Ratio only.
PB Ratio range over the past 10 years
Min: 6.5, Med: 27.83, Max: 391.93
Current: 9.05
6.5
391.93
PS Ratio 9.41
PS Ratio ranked higher than
59.50% of 726 companies
in the Biotechnology industry.
Industry Max: 113071.43, Med: 9999, Min: 0.01
INCY: 9.41
Ranked among companies with meaningful PS Ratio only.
PS Ratio range over the past 10 years
Min: 6.7, Med: 18.99, Max: 239.71
Current: 9.41
6.7
239.71
Price-to-Free-Cash-Flow 47.98
Price-to-Free-Cash-Flow ranked lower than
100.00% of 152 companies
in the Biotechnology industry.
Industry Max: 5923, Med: 37.07, Min: 0.04
INCY: 47.98
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
Price-to-Free-Cash-Flow range over the past 10 years
Min: 7.24, Med: 128.26, Max: 13461.43
Current: 47.98
7.24
13461.43
Price-to-Operating-Cash-Flow 39.92
Price-to-Operating-Cash-Flow ranked lower than
98.10% of 210 companies
in the Biotechnology industry.
Industry Max: 23050, Med: 29.99, Min: 0.04
INCY: 39.92
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
Price-to-Operating-Cash-Flow range over the past 10 years
Min: 7.19, Med: 92.77, Max: 974.08
Current: 39.92
7.19
974.08
EV-to-EBIT 65.34
EV-to-EBIT ranked lower than
100.00% of 261 companies
in the Biotechnology industry.
Industry Max: 4391.42, Med: 22.17, Min: 0.02
INCY: 65.34
Ranked among companies with meaningful EV-to-EBIT only.
EV-to-EBIT range over the past 10 years
Min: -8534.9, Med: -9.6, Max: 1569.2
Current: 65.34
-8534.9
1569.2
EV-to-EBITDA 53.89
EV-to-EBITDA ranked lower than
100.00% of 281 companies
in the Biotechnology industry.
Industry Max: 28816.43, Med: 18.08, Min: 0.02
INCY: 53.89
Ranked among companies with meaningful EV-to-EBITDA only.
EV-to-EBITDA range over the past 10 years
Min: -8534.9, Med: -11.4, Max: 1569.2
Current: 53.89
-8534.9
1569.2
EV-to-Revenue 8.56
EV-to-Revenue ranked higher than
64.72% of 771 companies
in the Biotechnology industry.
Industry Max: 118933, Med: 13.69, Min: 0.05
INCY: 8.56
Ranked among companies with meaningful EV-to-Revenue only.
EV-to-Revenue range over the past 10 years
Min: 6, Med: 19.5, Max: 273.2
Current: 8.56
6
273.2
Current Ratio 5.22
Current Ratio ranked lower than
51.02% of 1074 companies
in the Biotechnology industry.
Industry Max: 3987.61, Med: 4.46, Min: 0.01
INCY: 5.22
Ranked among companies with meaningful Current Ratio only.
Current Ratio range over the past 10 years
Min: 1.51, Med: 4.34, Max: 21.14
Current: 5.22
1.51
21.14
Quick Ratio 5.21
Quick Ratio ranked higher than
51.77% of 1074 companies
in the Biotechnology industry.
Industry Max: 3987.61, Med: 4.18, Min: 0.01
INCY: 5.21
Ranked among companies with meaningful Quick Ratio only.
Quick Ratio range over the past 10 years
Min: 1.51, Med: 4.32, Max: 21.14
Current: 5.21
1.51
21.14
Days Inventory 22.65
Days Inventory ranked higher than
86.90% of 481 companies
in the Biotechnology industry.
Industry Max: 908.49, Med: 125.55, Min: 0.02
INCY: 22.65
Ranked among companies with meaningful Days Inventory only.
Days Inventory range over the past 10 years
Min: 14.47, Med: 26.08, Max: 323.15
Current: 22.65
14.47
323.15
Days Sales Outstanding 44.60
Days Sales Outstanding ranked lower than
52.10% of 668 companies
in the Biotechnology industry.
Industry Max: 1096.56, Med: 64.17, Min: 0.06
INCY: 44.6
Ranked among companies with meaningful Days Sales Outstanding only.
Days Sales Outstanding range over the past 10 years
Min: 12.25, Med: 52.27, Max: 6447.52
Current: 44.6
12.25
6447.52
Days Payable 260.52
Days Payable ranked higher than
86.19% of 536 companies
in the Biotechnology industry.
Industry Max: 1651.36, Med: 63.91, Min: 0.12
INCY: 260.52
Ranked among companies with meaningful Days Payable only.
Days Payable range over the past 10 years
Min: 260.52, Med: 474.22, Max: 32457.1
Current: 260.52
260.52
32457.1

Dividend & Buy Back

Current vs industry vs history
3-Year Share Buyback Rate -4.50
3-Year Share Buyback Rate ranked higher than
69.19% of 857 companies
in the Biotechnology industry.
Industry Max: 43.5, Med: -13.4, Min: -1815.4
INCY: -4.5
Ranked among companies with meaningful 3-Year Share Buyback Rate only.
3-Year Share Buyback Rate range over the past 10 years
Min: -17.8, Med: -7.6, Max: -0.6
Current: -4.5
-17.8
-0.6

Valuation & Return

Current vs industry vs history
Price-to-Tangible-Book 10.97
Price-to-Tangible-Book ranked lower than
74.61% of 894 companies
in the Biotechnology industry.
Industry Max: 800, Med: 5.32, Min: 0.05
INCY: 10.97
Ranked among companies with meaningful Price-to-Tangible-Book only.
Price-to-Tangible-Book range over the past 10 years
Min: 0.91, Med: 6.76, Max: 340.56
Current: 10.97
0.91
340.56
Price-to-Projected-FCF 6.94
Price-to-Intrinsic-Value-Projected-FCF ranked lower than
82.90% of 193 companies
in the Biotechnology industry.
Industry Max: 117, Med: 3.12, Min: 0.09
INCY: 6.94
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
Price-to-Intrinsic-Value-Projected-FCF range over the past 10 years
Min: 5.95, Med: 16.69, Max: 138.66
Current: 6.94
5.95
138.66
Price-to-Median-PS-Value 0.50
Price-to-Median-PS-Value ranked higher than
83.92% of 678 companies
in the Biotechnology industry.
Industry Max: 126.94, Med: 0.92, Min: 0.01
INCY: 0.5
Ranked among companies with meaningful Price-to-Median-PS-Value only.
Price-to-Median-PS-Value range over the past 10 years
Min: 0.12, Med: 0.88, Max: 11.57
Current: 0.5
0.12
11.57
Price-to-Graham-Number 6.02
Price-to-Graham-Number ranked lower than
100.00% of 200 companies
in the Biotechnology industry.
Industry Max: 68.46, Med: 2.27, Min: 0.02
INCY: 6.02
Ranked among companies with meaningful Price-to-Graham-Number only.
Price-to-Graham-Number range over the past 10 years
Min: 4.27, Med: 7.03, Max: 241
Current: 6.02
4.27
241
Earnings Yield (Joel Greenblatt) % 1.52
Earnings Yield (Greenblatt) ranked higher than
73.64% of 1081 companies
in the Biotechnology industry.
Industry Max: 5000, Med: -7.73, Min: -10000
INCY: 1.52
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
Earnings Yield (Greenblatt) range over the past 10 years
Min: -37.7, Med: -0.6, Max: 1.8
Current: 1.52
-37.7
1.8

More Statistics

Revenue (TTM) (Mil) $ 1,997.46
EPS (TTM) $ 1.17
Beta 1.01
Volatility % 34.05
52-Week Range $ 57 - 88.85
Shares Outstanding (Mil) 214.44

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 7
Positive ROA Y
Positive CFROA Y
Higher ROA yoy Y
CFROA > ROA Y
Lower Leverage yoy Y
Higher Current Ratio yoy Y
Less Shares Outstanding yoy N
Higher Gross Margin yoy Y
Higher Asset Turnover yoy N